Biotherapy Inc. Reports Clinical Results in Multiple Sclerosis
Patients; Study Supports the Company's Treatment
Advanced Biotherapy, Inc.
announced today the results of a 60 patient randomized, double
blind, placebo controlled clinical trial evaluating the efficacy
of its proprietary Anti-interferon-gamma drug (Anti-IFNg), for the
treatment of Secondary Progressive Multiple Sclerosis (MS)
The results showed
statistically significant improvements, at both six and 12 months
after treatment, when compared to both the placebo group and the
group treated with Anti-Tumor necrosis factor-alpha (Anti-TNFa).
The trial was conducted at the Russian State Medical University,
in Moscow, Russia.
Drug treatments were
administered twice daily for five days and an extensive battery of
clinical indices of disease progression were evaluated for a
period of one year post-treatment. The parameters evaluated
included Functional and Disability scores, Magnetic Resonance
Imaging (MRI), Evoked Potentials and various biochemical indices.
The 15 patients in the Anti-IFNg group, had statistically
significantly better outcomes at both six and 12 months treatment
when compared to either the 15 patients receiving a Placebo, 15
patients receiving Anti-TNFa, or the 15 patients treated with both
Commenting on the
results, Dr. Paul J. Marangos, Chairman and CEO of Advanced
Biotherapy, Inc. stated, "We are very pleased about the results of
this study demonstrating the superiority of our proprietary
Anti-IFNg approach for treating MS patients when compared to
Anti-TNFa." He added, "This study positions us favorably for the
continued development of this product."
Advanced Biotherapy, Inc. is
developing proprietary treatments for a range of autoimmune
diseases, including Rheumatoid Arthritis, Multiple Sclerosis, Type
I Diabetes and AIDS. The company's drugs neutralize
immunomodulators called Cytokines, which have now been shown to be
linked to these diseases.